Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2022-09-30 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于2022年度向特定对象发行A股股票预案修订情况说明的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the revision of a 2022 annual plan for a specific issuance of A shares to particular investors by the company 贝达药业股份有限公司. It details updates to the issuance plan, including changes in registered capital, background, purpose, shareholding, investment projects, and approval procedures. The document is relatively short (1755 characters) and primarily serves to inform about the revision and that the revised plan will be submitted to the shareholders' meeting for approval. It does not contain actual financial statements or detailed financial data but rather updates and explanations about the capital issuance plan. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2022-09-30 Chinese
2022年度向特定对象发行A股股票预案（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed plan and proposal for a specific issuance of A shares to a particular investor, who is the actual controller of the company. It includes extensive information about the issuance background, purpose, pricing, number of shares, lock-up period, use of proceeds, approvals required, and detailed information about the investor and related parties. The document references regulatory approvals from the Shenzhen Stock Exchange and the China Securities Regulatory Commission, and it is prepared according to relevant securities issuance regulations. The document is titled as a "2022年度向特定对象发行A股股票预案（修订稿）" which translates to "2022 Annual Plan for Private Placement of A Shares (Revised Draft)." This is a detailed issuance plan, not a simple announcement or a brief summary. It contains substantive content about the capital raising plan, including financial and strategic details. Therefore, it fits best under the category of Capital/Financing Update (CAP). It is not an Annual Report, Earnings Release, or Regulatory Filing. It is not a Proxy Statement or Voting Results. It is not a Management Report or Governance Information. It is a comprehensive document about a capital raising transaction by private placement to a specific investor, which is the actual controller, including detailed terms and conditions, pricing, and use of proceeds. Hence, the classification is CAP with high confidence.
2022-09-30 Chinese
监事会对公司调整后的2022年度向特定对象发行A股股票文件的书面审核意见
Regulatory Filings Classification · 95% confidence The document is a written supervisory board opinion on the company's adjusted 2022 private placement of A shares. It references compliance with company law, securities law, and China Securities Regulatory Commission rules, and discusses the issuance plan, feasibility, pricing fairness, and related party transactions. The document is a formal review and approval opinion rather than the issuance plan itself or a financial report. It does not contain financial statements or results but is an official supervisory board opinion on the issuance documents. This fits best under Regulatory Filings (RNS) as it is a compliance and supervisory opinion related to a capital issuance but not the issuance announcement or financial report itself. The document length is short (1611 characters), and it is not a report publication announcement or certification letter but a formal supervisory opinion.
2022-09-30 Chinese
独立董事关于第三届董事会第三十六次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at the 36th meeting of the third board of directors of Betta Pharmaceuticals Co., Ltd. It includes detailed opinions on a specific proposal for a private placement of A shares in 2022, feasibility analysis, related party transactions, dilution impact and compensation measures, and nomination of board candidates. The content is focused on governance and board-level decisions related to capital raising and board nominations. It is not a full annual report, audit report, or earnings release. It is not a simple announcement or certification but a detailed board/management related document. The document length is 4398 characters, which is relatively short but contains substantive independent opinions on board matters. Therefore, the best fitting category is Board/Management Information (MANG), as it announces and discusses changes and proposals at the board level, including director nominations and capital raising plans requiring shareholder approval.
2022-09-30 Chinese
独立董事关于第三届董事会第三十六次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding the pre-approval of matters to be discussed at the 36th meeting of the third board of directors of Betta Pharmaceuticals Co., Ltd. It focuses on the company's 2022 plan for a private placement of A shares, including feasibility analysis, use of proceeds, and related party transactions. The document references regulatory frameworks and laws relevant to securities issuance and corporate governance in China. The content is about the independent directors' pre-approval opinions on the issuance plan and related reports, not the issuance plan itself or the actual financial report. The document length is 2959 characters, which is relatively short and consistent with an announcement or opinion rather than a full report. It does not contain financial statements or detailed financial data but is a formal pre-approval opinion related to board meeting agenda items. Therefore, this document fits best under Board/Management Information (MANG), as it relates to board meeting matters and approvals rather than a full report or announcement of voting results.
2022-09-30 Chinese
截至2022年6月30日止前次募集资金使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集资金使用情况报告" which translates to "Report on the Use of Previously Raised Funds" as of June 30, 2022. It references regulatory requirements from the China Securities Regulatory Commission and details the amounts raised from public and private stock issuances, the storage and use of these funds, changes in investment projects, and economic benefits realized from these investments. The document includes detailed financial tables and explanations about the use and management of the raised capital. This type of report is a specialized disclosure on the use of capital raised from equity offerings, which aligns with the category of Capital/Financing Update (CAP). It is not a full annual or interim report, nor an earnings release or audit report. It is a detailed update on fundraising and the use of those funds, consistent with the CAP category.
2022-09-30 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.